Abstract
Human papillomavirus (HPV) infection is the commonest sexually transmitted infection globally. Many other types of sexually transmitted infections have been considered as co-factors for HPV infection, ranging from Neisseria gonorrhoeae to Chlamydia trachomatis to herpes simplex 2, to name a few. HPV infection, persistent infection with high-risk types, infection with multiple types as well as cervical cancer and its precursors are known to be more prevalent in human immunodeficiency virus (HIV)-infected women. Whether HPV infection stimulates transmission of HIV is still controversial but if this is true, HPV vaccination to prevent HPV infection, particularly with types 16 and 18, may have a significant public health impact. HPV vaccination has been shown to be highly effective in preventing disease caused by its target types, e.g. 16/18 (bivalent vaccine) and 16/18/6/11 (quadrivalent) and appear to be as safe and immunogenic in HIV-infected and HIV-uninfected individuals.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15. His article gives a global view of cancer and explains the methodology used by Globocan to analyse the data.
Munoz N, Castellsague X, de Gonzalez B, Gissman L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24S3:S3/1–S3/10.
Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.
Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Keertie V, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Eng J Med. 2003;348:518–27. This was the first article to classify HPV Into high and low risk types and is widely quoted.
de Sanjose S, Quint W, Alemany L, Geraets DT, Klaustermeier J, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide stidy. Lancet Oncol. 2010;11:1048–56.
Sankaranarayanan R, Swaminathan R, Brenner H, Chen K, Chia KS, Chen JG, et al. Cancer survival in Africa, Asia and Central America: a population based study. Lancet Oncol. 2010;11:165–73.
Gondos A, Brenner H, Wabinga H, Parking DM. Cancer survival in Kampala, Uganda. Br J Cancer. 2005;92(9):1808–12.
www.unaids.org/AIDSinfo—accessed May 1st, 2015
Harris TG, Burk RB, Palefsky JM, Massed LS, Bang YJ, Anastos K, et al. Incidence of cervical squamous intraepithelial lesions associated with HIV serostatus, CD4 cell counts and human papillomavirus test results. JAMA. 2005;293:1471–6.
Singh D, Anastos K, Hoover D, Burk R, Shi Q, Ngendahayo L, et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis. 2009;199(12):1851–61. One of the original articles showing the high incidence of HPV in HIV infected women with a control group.
Denny L, Boa R, Williamson A-L, Allan B, Hardie D, Ress S, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1 infected women.
McDonald AC, Tergas AI, Kuhn L, Denny L, Wright Jr TC. Distribution of human papillomavirus genotypes among HIV-positive and HIV—negative women in Cape Town, South Africa. Front Oncol. 2014;4:48. doi:10.3389/fonc.2014.00048.
Clifford GM, Concalves MA, Franceschi S. HPV, HIV study group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006;20(18):2337–44.
Denny L, Adewole I, Anorlu R, Dreyer G, Moodley M, Smith T, et al. Human papillomavirus prevalence and type distribution in invasive cervical cancer in sub-Saharan Africa. Int J Cancer. 2014;314:1389–98.
Schneider E, Whitmore S, Glynn KM, Dominquez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents and children <18 months and for HIV infection and AIDS among children aged 18 months to, 13 years—United States, 2008. MMWR Recomm Rep. 2008;57(RR-19):1–12.
Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581)(6):59–67.
Shiels MS, Pfeiffer RM, Gail MH, Iren-Hall H, Li J, Chaturvedi AK et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103:753–62.
Naucler P, da Costa FM, da Costa JL, Ljungberg O, Bugalho A and Dillner J. Human papillomavirus type-specific risk of cervical cancer in a population with a high human immunodeficiency virus prevalence: case control study. J Gen Virology 2011;92:2784–91.
Lissouba P, Van de Perre P, Auvert B. Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis. Sex Transm Infect. 2013;89:350–6. Useful review of the relationship between HPV and HIV.
Smith-McCune KK, Shiboski S, Chirenje MZ, Magure T, Tuveson J, Ma Y, et al. Type specific cervico-vaginal human papillomavirus infection increases risk of HIV acquisition independent of other sexually transmitted infections. PLoS One. 2010;5(4):e100940.
Smith JS, Moses S, Hudgens MG, Parker CB, Kawango A, Maclean I, et al. Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. J Infect Dis. 2010;201(11):1677–85.
Rositch AF, Gravitt PE, Smith JS. Growing evidence that HPV infection is associated with an increase in HIV acquisition: exploring the issue of HPV vaccination. Sex Trans Infect. 2013;89(5):357.
Denny L, Hendricks B, Gordon C, Thomas F, Hezareh M, Dobbelaere K, et al. Safety and immunogenicity if the HPV—16/18 ASO4 adjuvanted vaccine in HIV-positive women in South Africa: a partially blind randomised placebo-controlled trial. Vaccine. 2013;31(48):5745–53.
Rainone V, Glacomet V, Penagini F, Fabiano V, Calascibetta F, Mameli C, et al. Human papillomavirus vaccination induces strong virus specific cell-mediated immune responses in HIV-infected adolescents and young adults. AIDS. 2015;29:739–43.
Compliance with Ethics Guidelines
Conflict of Interest
Lynette Denny declares personal fees from Merck, GlaxosmithKline, and Roche for appearances on speaker’s forums.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Uterine Fibroids
Rights and permissions
About this article
Cite this article
Denny, L. HIV and HPV as Fatal Partners. Curr Obstet Gynecol Rep 4, 143–148 (2015). https://doi.org/10.1007/s13669-015-0122-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13669-015-0122-2